Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

123
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
123
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration01:28

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

98
Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.
98
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations01:15

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

134
Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
134
Rational Dosage Regimen: Maintenance Dose and Loading Dose01:24

Rational Dosage Regimen: Maintenance Dose and Loading Dose

5.0K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
5.0K
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

333
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
333
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses01:25

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

116
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
116

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Structure, assembly, and mechanism of the MmpL family of transporters.

Microbiology and molecular biology reviews : MMBR·2026
Same author

Hematopoietic Stem Cell Transplant and Brain Volume Changes in Adults With Sickle Cell Disease.

Neurology·2026
Same author

Essential role of MptB in the biosynthesis of phosphatidylinositol mannosides, lipomannan and lipoarabinomannan in mycobacteria.

The Journal of biological chemistry·2026
Same author

A periplasmic protein complex mediates arabinofuranosyltransferase activity and intrinsic drug resistance in <i>Mycobacterium tuberculosis</i>.

Science advances·2026
Same author

Transthyretin V122I variant and protein affect cardiac severity and mortality in sickle cell disease.

Blood advances·2026
Same author

Nonmyeloablative pentostatin-cyclophosphamide preconditioning improves rates of engraftment in adults undergoing haploidentical HCT for sickle cell disease.

PloS one·2026

Related Experiment Video

Updated: Dec 14, 2025

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
07:24

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy

1.9K

Computer Algorithm-Based Hydroxyurea Dosing Facilitates Titration to Maximum Tolerated Dose in Sickle Cell Anemia.

Mahogany Oldham1, Anna Conrey1, Corinne Pittman1

  • 1Sickle Cell Branch, NHLBI, NIH, Bethesda, Maryland, USA.

Journal of Clinical Pharmacology
|July 17, 2020
PubMed
Summary
This summary is machine-generated.

A new computer program effectively titrates hydroxyurea to its maximum tolerated dose for sickle cell disease (SCD) patients, improving fetal hemoglobin levels and reducing liver and kidney damage markers.

Keywords:
computer programhydroxyureamaximum tolerated doseorgan damagesickle cell disease

More Related Videos

Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry
08:23

Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry

Published on: November 5, 2019

10.2K
Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases
11:08

Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases

Published on: June 22, 2012

16.5K

Related Experiment Videos

Last Updated: Dec 14, 2025

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
07:24

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy

1.9K
Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry
08:23

Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry

Published on: November 5, 2019

10.2K
Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases
11:08

Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases

Published on: June 22, 2012

16.5K

Area of Science:

  • Hematology
  • Medical Informatics
  • Pharmacology

Background:

  • Sickle cell disease (SCD) is a debilitating condition leading to premature death.
  • Hydroxyurea therapy can prolong survival in SCD patients but is often underutilized due to dosing challenges.
  • Physician discomfort with hydroxyurea titration contributes to suboptimal patient adherence and outcomes.

Purpose of the Study:

  • To develop and evaluate a computer program for precise hydroxyurea titration to the maximum tolerated dose (MTD) in adults with SCD.
  • To assess the program's ability to standardize hydroxyurea dosing compared to manual methods.
  • To investigate the impact of MTD hydroxyurea on organ function markers in SCD.

Main Methods:

  • A single-arm, open-label pilot study involving 15 adult patients with homozygous SCD.
  • Ten patients were followed for one year after initiating or titrating hydroxyurea dose using the computer program.
  • Evaluation of fetal hemoglobin levels, organ damage markers (cardiopulmonary, liver, renal), and comparison of computer-guided vs. manual dosing decisions.

Main Results:

  • Fetal hemoglobin levels significantly increased from 8.3% to 25.1% (P < .001) in 10 patients.
  • Nine patients reached MTD within an average of 7.9 months; computer program recommendations matched manual decisions.
  • Significant reductions observed in direct bilirubin (P < .001) and alanine aminotransferase (P < .01); proteinuria decreased (P < .05).

Conclusions:

  • A computer program reliably and accurately titrates hydroxyurea to MTD in SCD patients.
  • The program simplifies hydroxyurea management, potentially increasing its utilization and patient benefit.
  • Further research with a larger cohort is warranted to validate the program's efficacy and explore its application as a downloadable tool.